Let's catch up on the latest news from the stock market. From significant investments to major deals, order wins, and appointments, here’s a quick look at which stocks will be in focus in today ...

Global healthcare company GlaxoSmithKline Pharmaceuticals Ltd on Tuesday (September 3) said it has received an income tax refund of ₹222.23 crore for the assessment year 2022-23, following an order ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Given the large stake in the stock by institutions, GSK's stock price might be vulnerable to their trading decisions 51% of the business is held by the top 25 shareholders Insiders have been ...

GSK Plc’s RSV vaccine has been approved for wider use in adults in Europe in a boost for the UK company’s blockbuster shot. The European Commission recommended GSK’s Arexvy for adults aged ...

Pharmaceutical giant GlaxoSmithKline (GSK) and rival drug manufacturers, including Sanofi, Pfizer and Boehringer Ingelheim, have won the right to an appeal hearing by the Delaware Supreme Court ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other cheap pharmaceutical stocks. The pharmaceutical industry is one of the most interesting sectors to ...

GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn drug Zantac causes cancer is scientifically sound. The British ...

The notice specifically concerns the acquisition of the Horlicks brand in India from GSK for ₹3,045 crore. Additionally, other GSKCH brands such as Boost, Maltova, and Viva were also added to ...

GSK (NYSE:GSK) stock was up 3% in afternoon trading Tuesday in the wake of a ruling by a Delaware court on whether certain evidence should be allowed in an ongoing case over the safety of its ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target of £16.50. The company’s shares closed last ...